GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Capital Expenditure

Avicanna (TSX:AVCN) Capital Expenditure : C$-0.50 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Avicanna Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Avicanna's cash flow for capital expenditures for the three months ended in Mar. 2025 was C$-0.14 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was C$-0.50 Mil.

Avicanna Capital Expenditure Historical Data

The historical data trend for Avicanna's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Capital Expenditure Chart

Avicanna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -1.69 -0.79 -0.07 -0.56 -0.40

Avicanna Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 - -0.05 -0.31 -0.14

Avicanna Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avicanna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Capital Expenditure
Comparable Companies
XCNQ:VEXT XCNQ:EPIC TSX:LABS TSXV:VM XCNQ:GWAY XCNQ:IAN XCNQ:CXXI TSXV:ROMJ XCNQ:OPTI NEOE:CBST ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
AVCNF:USA 0NN:Germany
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Website
https://www.avicanna.com
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
Executives
Sheldon Inwentash 10% Security Holder
Threed Capital Inc. 10% Security Holder
Phillip Cardella Senior Officer
Phillip Stanley Cardella Senior Officer
Aras Azadian Director, Senior Officer
Davender Sohi Senior Officer
David White Director
Kyle Lawrence Langstaff Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Chandra Panchal Director
Janet Giesselman Director

Avicanna Headlines

No Headlines